Wegovy HD 7.2 mg Side Effects: What's Different From the Standard Dose

With the FDA's approval of Wegovy HD (7.2 mg semaglutide injection) on March 19, 2026, patients now have access to a higher-dose GLP-1 agonist option designed for those seeking more aggressive weight management. While the standard 2.4 mg dose has long been the benchmark, the 7.2 mg formulation — studied in the STEP UP trial — offers enhanced efficacy but comes with a nuanced side effect profile. This article breaks down what's different, what to expect, and when to consult your healthcare provider.

Key Findings From the STEP UP Trial

The STEP UP trial evaluated the safety and efficacy of escalating semaglutide doses up to 7.2 mg weekly in adults with overweight or obesity. The study included over 2,000 participants and demonstrated a mean weight loss of approximately 20.7% at 72 weeks — a significant improvement over the 2.4 mg dose. However, the higher dose also revealed new safety signals, particularly in sensory and gastrointestinal domains.

Common Gastrointestinal Side Effects

As with all GLP-1 receptor agonists, gastrointestinal effects remain the most frequently reported adverse events. In the STEP UP trial, the incidence of common GI side effects at 7.2 mg was moderately higher than at 2.4 mg:

• Nausea: ~30% at 7.2 mg (vs. ~25% at 2.4 mg, ~10% placebo)
• Vomiting: ~15% at 7.2 mg (vs. ~10% at 2.4 mg, ~5% placebo)
• Diarrhea: ~20% at 7.2 mg (vs. ~14% at 2.4 mg, ~8% placebo)
• Constipation: ~15% at 7.2 mg (vs. ~12% at 2.4 mg, ~6% placebo)

These symptoms typically peak during the first 4–8 weeks of treatment and often subside as the body adapts. Gradual dose titration and adequate hydration are key strategies to mitigate these effects.

The New Finding: Dysesthesia at 7.2 mg

One of the most notable safety observations from the STEP UP trial was the emergence of dysesthesia — a neurological condition involving abnormal skin sensations such as burning, tingling, numbness, or heightened sensitivity. This was reported in approximately 4% of patients on 7.2 mg, compared to less than 1% in both the 2.4 mg and placebo groups.

While the exact mechanism is not yet fully understood, researchers suspect it may be related to semaglutide's impact on peripheral nerve signaling at higher concentrations. Importantly, most cases were mild to moderate and resolved spontaneously within 4–8 weeks, even without dose reduction. The FDA has initiated a post-marketing safety review to monitor long-term implications and gather additional data.

If you experience persistent tingling, burning, or unusual skin sensitivity while on Wegovy HD, report it to your healthcare provider. In most cases, the sensation is temporary and does not require discontinuation.

Discontinuation Rates

Discontinuation due to adverse events was slightly higher with Wegovy HD compared to the standard dose:

• 7.2 mg group: ~7.8%
• 2.4 mg group: ~5.1%
• Placebo: ~2.3%

The most common reasons for stopping treatment at the higher dose were GI intolerance (accounting for roughly 52% of discontinuations) and dysesthesia (approximately 18%). This underscores the importance of patient education and early intervention when side effects arise.

Side Effect Comparison: 7.2 mg vs 2.4 mg vs Placebo

Side Effect	7.2 mg	2.4 mg	Placebo
Nausea	30%	25%	10%
Vomiting	15%	10%	5%
Diarrhea	20%	14%	8%
Constipation	15%	12%	6%
Dysesthesia	4%	<1%	<1%
Discontinuation (AE)	7.8%	5.1%	2.3%

Who Should NOT Upgrade to Wegovy HD

Wegovy HD is not appropriate for everyone. You should not upgrade to the 7.2 mg dose if you:

• Could not tolerate the 2.4 mg dose — if you experienced severe GI side effects or required dose reduction at 2.4 mg, higher doses will likely worsen symptoms
• Have a history of pancreatitis — GLP-1 receptor agonists carry a risk of pancreatitis, which may increase at higher doses
• Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — this is an absolute contraindication for all semaglutide products
• Have severe kidney disease (eGFR <30 mL/min) — dehydration from GI side effects can compound renal issues
• Are pregnant or planning to become pregnant — discontinue semaglutide at least 2 months before a planned pregnancy

When to Talk to Your Doctor

Contact your healthcare provider promptly if you experience any of the following while on Wegovy HD:

• Severe or persistent nausea and vomiting that prevents adequate hydration
• Signs of pancreatitis — severe abdominal pain radiating to the back with nausea
• Unusual skin sensations (burning, tingling, numbness) that interfere with daily activities
• Signs of an allergic reaction — rash, swelling of the face or throat, difficulty breathing
• Dark urine or significantly decreased urine output — possible signs of kidney stress

Medical Disclaimer

Wegovy HD (semaglutide 7.2 mg) is a prescription medication approved for chronic weight management. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Individual responses to treatment may vary, and not all patients will experience the same side effects or outcomes. If you have questions about your specific medical situation, speak with a qualified healthcare professional.